Preventing tumour recurrence
For cancer survivors, the fight isn’t always over. Many are concerned about the possibility of recurrence, and living with uncertainty is never easy. Discovering an intervention that can prevent cancer recurrence has the potential to significantly enhance quality of life.

Fighting the main threat: metastasis
Evidence is occasionally discovered supporting various, often simple interventions that improve existing treatment protocols. These additional therapies prevent tumour recurrence and contribute significantly to better outcomes. With 90% of deaths resulting from tumour recurrence and metastasis, primary tumours are not the main threat. While the mechanism of action of several interventions are not yet fully understood, research indicates that their influence on dormant cancer cells and the body’s own cancer-fighting mechanisms are at the core of their potential.
Our trials in this focus area
- Digestive cancer
- Breast cancer
Onze focus
-
Drug repurposing
[in het Engels] Drug repurposing, also known as drug repositioning, is a drug development strategy predicated on the... -
Minder vaak voorkomende en zeldzame kankers
[in het Engels] We don’t just focus on the ‘big four’ of cancer – prostate, colon, breast and lung. -
Combinatietherapieën
[in het Engels] It is important to investigate the impacts of drugs beyond what they can achieve alone. Using them in... -
Herval voorkomen
[in het Engels] For cancer survivors, the fight isn’t always over. Many are concerned about the possibility of...
ONZE BELOFTE
-
We investeren in het meest veelbelovende wetenschappelijk onderzoek om meetbare vooruitgang te maken in de strijd tegen kanker.
-
Een beter en een langer leven voor de patiënt is het enige doel dat we nastreven. Financieel rendement is geen thema voor ons.
-
We gaan op zoek naar opportuniteiten in kankeronderzoek die zullen leiden tot pragmatische oplossingen voor patiënten in nood.
-
We streven naar impact en investeren onze middelen daar waar we de snelste vooruitgang zullen boeken.
-
Elke kanker verdient evenveel aandacht, ongeacht de prevalentie of de rendabiliteit.